340B Drug Discount Program Hits A Turning Point, But In Which Direction?
This article was originally published in RPM Report
Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.
Register for our free email digests: